Company News Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders Suzhou, China – January 29, 2024 – Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the…ractigenJanuary 29, 2024
Company NewsHomepage News Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01 JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…ractigenDecember 6, 2023
Company News Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…EnvisionNovember 2, 2023
Company News Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…EnvisionJune 10, 2023
Company News Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically…ractigenJune 10, 2023
Company News Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…EnvisionMarch 3, 2023
Company NewsHomepage News Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…EnvisionJanuary 27, 2022
Company NewsHomepage News Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…EnvisionFebruary 10, 2021
Company NewsHomepage News CB Insights lists Ractigen as one of the Top RNA biotech companies in China Today, CB Insights China published, for the first time, a top list of RNA biotech…EnvisionMay 19, 2020
Company News Delegation from Nantong University Medical School visits Ractigen Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical…EnvisionJuly 11, 2018